In Brief: NDMA attapulgite trial
This article was originally published in The Tan Sheet
Executive Summary
NDMA attapulgite trial: FDA informs NDMA in a recent letter of an internal agency meeting on May 13 to address the trade association's proposal for analyzing data from its attapulgite trial. FDA's letter responds to a request for feedback on the design of the study, which will compare effectiveness of attapulgite and placebo in treating acute non-specific diarrhea. NDMA has nearly completed enrollment in the study. The study will evaluate subjects in Mexico and Jamaica who are found to have pathogen-negative stools. "The Tan Sheet" mistakenly reported (June 3, In Brief) that the pathogen-positive subgroup would be the central focus of the study...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning